Frailty-A promising concept to evaluate disease vulnerability

被引:25
作者
Ribeiro, Ana Rita [1 ]
Howlett, Susan E. [2 ,3 ]
Fernandes, Adelaide [1 ,4 ]
机构
[1] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Neuron Glia Biol Hlth & Dis, Lisbon, Portugal
[2] Dalhousie Univ, Dept Pharmacol, Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3H 4R2, Canada
[3] Dalhousie Univ, Dept Med Geriatr Med, Halifax, NS, Canada
[4] Univ Lisbon, Fac Pharm, Dept Biochem & Human Biol, Lisbon, Portugal
关键词
Frailty; Human immunodeficiency virus; Dementia; Cancer; Cardiovascular diseases; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; CANCER-PATIENTS; SEX-DIFFERENCES; HEART-FAILURE; HIV-INFECTION; OLDER-ADULTS; RISK-FACTORS; INFLAMMATION; AGE;
D O I
10.1016/j.mad.2020.111217
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
With the emergence of diseases, people become frailer and are expected to be less tolerant of adverse outcomes. Frailty was first described to explain the variability in life expectancy in individuals of the same age. Nowadays, it is described as a syndrome and as a state. It is used to explain the heterogeneity of people not only in their responses to biological ageing but also in their responses to illness. In this review, we explore the role of frailty both in age-related diseases, including dementia, cancer and cardiovascular disease, and in non-age-related diseases, such as Human Immunodeficiency Virus. We describe how high levels of frailty in such disorders predict worse outcomes and play a direct role in disease progression and in prognostic prediction. Overall, the potential for frailty to predict adverse health outcomes among young people as well as in non-age-related diseases is an evolving topic. Understanding how frailty contributes to poor health and how it can be modified to prevent or delay disease progression will ultimately enhance quality of life in affected individuals.
引用
收藏
页数:8
相关论文
共 89 条
[1]   Frailty in Patients with Cardiovascular Disease: Why, When, and How to Measure [J].
Afilalo J. .
Current Cardiovascular Risk Reports, 2011, 5 (5) :467-472
[2]  
[Anonymous], 2021, HIV/AIDS
[3]  
[Anonymous], [No title captured]
[4]  
[Anonymous], 2018, BEROERTE GT CIJFERS
[5]  
[Anonymous], [No title captured]
[6]   Updated research nosology for HIV-associated neurocognitive disorders [J].
Antinori, A. ;
Arendt, G. ;
Becker, J. T. ;
Brew, B. J. ;
Byrd, D. A. ;
Cherner, M. ;
Clifford, D. B. ;
Cinque, P. ;
Epstein, L. G. ;
Goodkin, K. ;
Gisslen, M. ;
Grant, I. ;
Heaton, R. K. ;
Joseph, J. ;
Marder, K. ;
Marra, C. M. ;
McArthur, J. C. ;
Nunn, M. ;
Price, R. W. ;
Pulliam, L. ;
Robertson, K. R. ;
Sacktor, N. ;
Valcour, V. ;
Wojna, V. E. .
NEUROLOGY, 2007, 69 (18) :1789-1799
[7]   Frailty Prevalence and Characteristics in Older Adults with Hematologic Cancer: a Descriptive Study [J].
Atakul, Esra ;
Akyar, Imatullah .
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2019, 6 (01) :43-49
[8]   Pathophysiology of heart failure and frailty: a common inflammatory origin? [J].
Bellumkonda, Lavanya ;
Tyrrell, Daniel ;
Hummel, Scott L. ;
Goldstein, Daniel R. .
AGING CELL, 2017, 16 (03) :444-450
[9]  
Bennett DA, 2012, CURR ALZHEIMER RES, V9, P617
[10]   The aging of the HIV epidemic [J].
Bhavan K.P. ;
Kampalath V.N. ;
Overton E.T. .
Current HIV/AIDS Reports, 2008, 5 (3) :150-158